参考文献/References:
[1]Gargallo CJ,Lué A,Gomollón F.Biosimilars in inflammatory bowel disease[J].Minerva Medica,2017,108(3):239-254. [2]Torres J,Mehandru S,Colombel JF,et al.Crohn’s disease[J].Lancet(London, England),2017,389(10080):1741-1755. [3]Turpin W,Lee SH,Raygoza Garay JA,et al.Increased Intestinal Permeability Is Associated With Later Development of Crohn’s Disease[J].Gastroenterology,2020,159(6):2092-2100.e5. [4]Fasano A.Zonulin and its regulation of intestinal barrier function: the biological door to inflammation,autoimmunity,and cancer[J].Physiological Reviews,2011,91(1):151-175. [5]Ma C,Battat R,Khanna R,et al.What is the role of C-reactive protein and fecal calprotectin in evaluating Crohn’s disease activity[J].Best Pract Res Clin Gastroenterol,2019(38-39):101602. [6]Schoultz I,Keita AV.The Intestinal Barrier and Current Techniques for the Assessment of Gut Permeability[J].Cells,2020,9(8):1909. [7]Sgambato D,Gimigliano F,De Musis C,et al.Bone alterations in inflammatory bowel diseases[J].World J Clin Cases,2019,7(15):1908-1925. [8]Hidalgo DF,Boonpheng B,Phemister J,et al.Inflammatory Bowel Disease and Risk of Osteoporotic Fractures:A Meta-Analysis[J].Cureus,2019,11(9):e5810. [9]Szafors P,Che H,Barnetche T,et al.Risk of fracture and low bone mineral density in adults with inflammatory bowel diseases.A systematic literature review with meta-analysis[J].Osteoporos Int,2018,29(11):2389-2397. [10]Hoffmann P,Krisam J,Kasperk C,et al.Prevalence, Risk Factors and Course of Osteoporosis in Patients with Crohn’s Disease at a Tertiary Referral Center[J].J Clin Med,2019,8(12):2178. [11]Krela-Kazmierczak I,Kaczmarek-RysM,Szymczak A,et al.Bone Metabolism and the c.-223C>T Polymorphism in the 5’UTR Region of the Osteoprotegerin Gene in Patients with Inflammatory Bowel Disease[J].Calcif Tissue Int,2016,99(6):616-624. [12]Owczarek D,Cibor D,Glowacki MK,et al.TNF-α and soluble forms of TNF receptors 1 and 2 in the serum of patients with Crohn’s disease and ulcerative colitis[J].Pol Arch Med Wewn,2012,122(12):616-623. [13]Frigstad SO,Hoivik ML,Jahnsen J,et al.Pain Severity and Vitamin D Deficiency in IBD Patients[J].Nutrients,2019,12(1):26. [14]Luo JS,Zhao X,Yang Y.Effects of emodin on inflammatory bowel disease-related osteoporosis[J].Biosci Rep,2020,40(1):BSR20192317. [15]Pierote NR,Braz AF,Barros SL,et al.Effect of mineral status and glucocorticoid use on bone mineral density in patients with Crohn’s disease[J].Nutrition,2018(48):13-17. [16]Zittan E,Kelly OB,Kirsch R,et al.Low Fecal Calprotectin Correlates with Histological Remission and Mucosal Healing in Ulcerative Colitis and Colonic Crohn’s Disease[J].Inflamm Bowel Dis,2016,22(3):623-630. [17]Novak G,Parker CE,Pai RK,et al.Histologic scoring indices for evaluation of disease activity in Crohn’s disease[J].Cochrane Database Syst Rev,2017,7(7):CD012351. [18]Veauthier B,Hornecker JR.Crohn’s Disease:Diagnosis and Management[J].Am Fam Physician,2018,98(11):661-669. [19]Lima CA,Lyra AC,Mendes CMC,et al.Bone mineral density and inflammatory bowel disease severity[J].Braz J Med Biol Res,2017,50(12):e6374. [20]Awad WA,Hess C,Hess M.Enteric Pathogens and Their Toxin-Induced Disruption of the Intestinal Barrier through Alteration of Tight Junctions in Chickens[J].Toxins (Basel),2017,9(2):60. [21]Kevans D,Turpin W,Madsen K,et al.Determinants of intestinal permeability in healthy first-degree relatives of individuals with Crohn’s disease[J].Inflamm Bowel Dis,2015,21(4):879-887. [22]Michielan A,D’Incà R.Intestinal Permeability in Inflammatory Bowel Disease:Pathogenesis,Clinical Evaluation,and Therapy of Leaky Gut[J].Mediators Inflamm,2015(2015):628157. [23]Sturgeon C,Fasano A.Zonulin,a regulator of epithelial and endothelial barrier functions,and its involvement in chronic inflammatory diseases[J].Tissue Barriers,2016,4(4):e1251384. [24]Tajik N,Frech M,Schulz O,et al.Targeting zonulin and intestinal epithelial barrier function to prevent onset of arthritis[J].Nat Commun,2020,11(1):1995. [25]Schepper JD,Collins F,Rios-Arce ND,et al.Involvement of the Gut Microbiota and Barrier Function in Glucocorticoid-Induced Osteoporosis[J].J Bone Miner Res,2020,35(4):801-820. [26]Clairembault T,Leclair-Visonneau L,Coron E,et al.Structural alterations of the intestinal epithelial barrier in Parkinson’s disease[J]. Acta Neuropathologica Communications,2015(3):12. [27]Van Spaendonk H,Ceuleers H,Witters L,et al.Regulation of intestinal permeability:The role of proteases[J].World Journal of Gastroenterology,2017,23(12):2106-2123. [28]Kitaura H,Marahleh A,Ohori F,et al.Osteocyte-Related Cytokines Regulate Osteoclast Formation and Bone Resorption[J].Int J Mol Sci,2020,21(14):5169. [29]Cornick S,Tawiah A,Chadee K.Roles and regulation of the mucus barrier in the gut[J].Tissue Barriers,2015,3(1-2):e982426.
相似文献/References:
[1]王 忻,赵 毅,朱 悦,等.甲状旁腺激素应用于大鼠脊髓损伤后防治骨质疏松的效果分析[J].医学信息,2018,31(02):54.[doi:10.3969/j.issn.1006-1959.2018.02.019]
WANG Xin,ZHAO Yi,ZHU Yue,et al.Effect of Parathyroid Hormone on Prevention and Treatment of
Osteoporosis after Spinal Cord Injury in Rats[J].Medical Information,2018,31(08):54.[doi:10.3969/j.issn.1006-1959.2018.02.019]
[2]吴玲,李玉兰.个性化心理护理干预应用于骨质疏松的临床效果观察[J].医学信息,2018,31(01):158.[doi:10.3969/j.issn.1006-1959.2018.01.062]
WU Ling,LI Yu-lan.The Clinical Effect of Personalized Psychological Nursing Intervention on Osteoporosis[J].Medical Information,2018,31(08):158.[doi:10.3969/j.issn.1006-1959.2018.01.062]
[3]刘小花.经皮穿刺椎体成形术治疗老年性骨质疏松性
椎体压缩骨折的疗效分析[J].医学信息,2018,31(05):186.[doi:10.3969/j.issn.1006-1959.2018.05.070]
LIU Xiao-hua.The Effect of Percutaneous Vertebroplasty in the Treatment of Senile Osteoporotic Vertebral Compression Fracture[J].Medical Information,2018,31(08):186.[doi:10.3969/j.issn.1006-1959.2018.05.070]
[4]杨可佳,孙春华,洪全明,等.经皮椎体成形术治疗骨质疏松性压缩性椎体骨折的疗效观察[J].医学信息,2018,31(17):98.[doi:10.3969/j.issn.1006-1959.2018.17.030]
YANG Ke-jia,SUN Chun-hua,HONG Quan-ming,et al.Therapeutic Effect of Percutaneous Vertebroplasty for treatment of Osteoporotic Vertebral Compression Fracture[J].Medical Information,2018,31(08):98.[doi:10.3969/j.issn.1006-1959.2018.17.030]
[5]蒋俊良.老年股骨转子间骨折的手术治疗方法[J].医学信息,2018,31(23):58.[doi:10.3969/j.issn.1006-1959.2018.23.017]
JIANG Jun-liang.Research Progress of Intertrochanteric Fractures of Femurin the Elderly[J].Medical Information,2018,31(08):58.[doi:10.3969/j.issn.1006-1959.2018.23.017]
[6]曾 翔,文 星,常一航,等.营养风险筛查和BMI在克罗恩病患者营养评估中的应用[J].医学信息,2019,32(08):133.[doi:10.3969/j.issn.1006-1959.2019.08.039]
ZENG Xiang,WEN Xing,CHANG Yi-hang,et al.Application of Nutritional Risk Screening and BMI in Nutritional Assessment of Patients with Crohn's Disease[J].Medical Information,2019,32(08):133.[doi:10.3969/j.issn.1006-1959.2019.08.039]
[7]张 强,杨 帆,陈 康,等.椎体成形术中明胶海绵填塞治疗椎体前壁破损的
OVCFs的临床疗效观察[J].医学信息,2019,32(11):85.[doi:10.3969/j.issn.1006-1959.2019.11.023]
ZHANG Qiang,YANG Fan,CHEN Kang,et al.Clinical Observation of OVCFs in the Treatment of Anterior Wall Fracture of
Vertebral Body with Gelatin Sponge During Vertebroplasty[J].Medical Information,2019,32(08):85.[doi:10.3969/j.issn.1006-1959.2019.11.023]
[8]庞 渊,张 庆,阿伍提·艾克木,等.经皮椎体成形术治疗骨质疏松性椎体压缩性骨折的
疗效分析[J].医学信息,2019,32(11):116.[doi:10.3969/j.issn.1006-1959.2019.11.033]
PANG Yuan,ZHANG Qing,Awti Aikemu,et al.Therapeutic Effect of Percutaneous Vertebroplasty in the Treatment of
Osteoporotic Vertebral Compression Fractures[J].Medical Information,2019,32(08):116.[doi:10.3969/j.issn.1006-1959.2019.11.033]
[9]罗巧彦,凌止发,严宗逊,等.中老年女性骨代谢指标与骨质疏松的相关性研究[J].医学信息,2019,32(17):68.[doi:10.3969/j.issn.1006-1959.2019.17.021]
LUO Qiao-yan,LING Zhi-fa,YAN Zong-xun,et al.Correlation between Bone Metabolic Markers and Osteoporosis in Middle-aged and Elderly Women[J].Medical Information,2019,32(08):68.[doi:10.3969/j.issn.1006-1959.2019.17.021]
[10]熊义博,刘学员,邓泽熙,等.老年人骨质疏松与动脉硬化的关系[J].医学信息,2019,32(19):106.[doi:10.3969/j.issn.1006-1959.2019.19.033]
XIONG Yi-bo,LIU Xue-yuan,DENG Ze-xi,et al.Relationship Between Osteoporosis and Arteriosclerosis in the Elderly[J].Medical Information,2019,32(08):106.[doi:10.3969/j.issn.1006-1959.2019.19.033]